Sage Therapeutics, Inc. (SAGE) stock prices updated...
 

Sage Therapeutics, Inc. stock price

Sage Therapeutics, Inc. latest news:


  • 11/14/2017 21:14:59

    BRIEF-Sage Therapeutics prices public offering of 3.53 mln common shares at $85/share

    * SAYS PUBLIC OFFERING OF 3.53 MILLION COMMON SHARES PRICED AT $85.00PER SHARE Source text for Eikon: Further company coverage:

  • 11/13/2017 14:05:38

    BRIEF-Sage Therapeutics announces proposed public offering of common stock

    * Sage Therapeutics announces proposed public offering of common stock

  • 11/09/2017 10:05:31

    Sage Therapeutics Wins Big in Depression Trial


  • 11/09/2017 10:00:12

    Sage Therapeutics stock bounces 49% after positive results for depression treatment

    Positive postpartum depression results have investors looking to Sage's major depressive disorder drug, with results expected this year. Mere months after Sage Therapeutics Inc.' s brexanolone therapy failed in a different disease area, the company and its drug had an improbable comeback in postpartum depression, reporting positive results in two late-stage clinical trials. Sage shares surged 49% in extremely heavy morning trade Thursday after the announcement.

  • 11/09/2017 07:36:53

    Dow opens more than 100 points lower, flirts with worst daily decline in 2 months

    U.S. stocks opened firmly lower on Thursday as Wall Street awaited the Senate version of a GOP-led tax bill, with the investors appearing to wager that the prospects for passage of reforms to tax policy soon were low. The Dow Jones Industrial Average fell 100 points, or 0.4%, 23,466, threatening to fall the most since Sept. 5, the S&P 500 index slipped 13 points, or 0.5% at 2,581, while the Nasdaq Composite Index were down 0.8% at 6,735. All three benchmarks closed at a records simultaneously on Wednesday, but only booked slight gains in doing so. In economic news, weekly jobless claims, a proxy for layoffs across the U.S., increased 10,000 to a seasonally adjusted 239,000 in the week ended Nov. 4, the Labor Department said. However, the levels still reflect a labor market that is healthy. In corporate news, Kohl's Corp. shares tumbled after lowering its 2018 earnings outlook and reporting quarterly profit that was slightly weaker than expected, though earnings exceeded estimates. Sage Therapeutics Inc. shares surged after the company said its postpartum-depression therapy has positive results in two late-stage clinical trials.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/09/2017 07:33:56

    Dow opens more than 100 points lower, on track for worst daily decline in 2 months

    U.S. stocks opened firmly lower on Thursday as Wall Street awaited the Senate version of a GOP-led tax bill, with the investors appearing to wager that the prospects for passage of reforms to tax policy soon were low. The Dow Jones Industrial Average fell 90, or 0.5%, 23,460, flirting with it threatening to fall the most since Sept. 5, the S&P 500 index slipped 12 points, or 0.5% at 2,581, while the Nasdaq Composite Index were down 0.7% at 6,741. All three benchmarks closed at a records simultaneously on Wednesday, but only booked slight gains in doing so. In economic news, weekly jobless claims, a proxy for layoffs across the U.S., increased 10,000 to a seasonally adjusted 239,000 in the week ended Nov. 4, the Labor Department said. However, the levels still reflect a labor market that is healthy. In corporate news, Kohl's Corp. shares tumbled after lowering its 2018 earnings outlook and reporting quarterly profit that was slightly weaker than expected, though earnings exceeded estimates. Sage Therapeutics Inc. shares surged after the company said its postpartum-depression therapy has positive results in two late-stage clinical trials.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/09/2017 04:31:36

    Sage Therapeutics postpartum depression drug meets goal in two trials

    Sage Therapeutics(SAGE) on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies, sending shares of the company up about 17 percent in pre-market trade. The drug, brexanolone, achieved lower rates of depression in patients compared with a placebo in both trials.

  • 09/15/2017 15:10:21

    Neos Therapeutics shares fall after FDA approves new formulation of ADHD drug

    Shares of Neos Therapeutics Inc. fell more than 5% late Friday after the pharmaceutical company said the U.S. Food and Drug Administration has approved one of its extended-release drugs for Attention Deficit Hyperactive Disorder in an oral-suspension form. "This FDA approval unlocks yet another treatment option for ADHD patients and their caregivers who are seeking a liquid extended-release amphetamine product and provides a different dosage form of our already-approved Adzenys XR-ODT," Neos Therapeutics Chief Vipin K. Garg said in a statement. The FDA has aproved three ADHD drugs by Neos in two years, which "speaks to the strength of our technology platform," he said. The new formulation is expected to be commercially launched in early 2018, the company said. The shares ended the regular trading day up 2.2%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/12/2017 14:31:16

    DowDuPont and US Bancorp climb while Cooper Cos. slides

    DowDuPont and US Bancorp advance while Cooper Cos. and Sage Therapeutics falls

  • More trends:

    Sagent Pharmaceuticals, Inc.SGNT | Saia, Inc.SAIA | Sajan, Inc.SAJA | Salem Media Group, Inc.SALM | Salisbury Bancorp, Inc.SAL | Sanderson Farms, Inc.SAFM | SanDisk CorporationSNDK | Sandy Spring Bancorp, Inc.SASR | Sangamo BioSciences, Inc.SGMO | Sanmina CorporationSANM |